Lenvima (lenvatinib) / Eisai, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 53 Diseases   490 Trials   490 Trials   8927 News 


«12...4950515253545556575859...123124»
  • ||||||||||  Welireg (belzutifan) / Merck (MSD)
    BELZUTIFAN-INDUCED HYPERSENSITIVITY PNEUMONITIS (Convention Center Exhibit Hall: Poster Area) -  Sep 11, 2022 - Abstract #CHEST2022CHEST_3979;    
    Her cancer diagnosis was established in 2019 and had undergone cytoreductive nephrectomy and treatment with axitinib/pembrolizumab...Due to further disease progression, she was transitioned to lenvatinib/everolimus, though the treatment was discontinued due to anorexia and worsening pulmonary symptoms...She was covered with azithromycin/ceftriaxone along with high-dose steroids and was admitted to the stepdown unit for further management... We report the only known case of Belzutifan-induced hypersensitivity pneumonitis and hope this case will become a useful contribution to the literature.
  • ||||||||||  Review, Journal:  Anti-obesity carbonic anhydrase inhibitors: challenges and opportunities. (Pubmed Central) -  Sep 11, 2022   
    Classical drug design studies of sulphonamides, sulfamates and sulfamides afforded low nanomolar mitochondrial CA-selective inhibitors, but detailed antiobesity studies were poorly performed with most of them. A breakthrough in the field may be constituted by the design of hybrids incorporating CAIs and other antiobesity chemotypes.
  • ||||||||||  simvastatin / Generic mfg., lenvatinib / Generic mfg., sorafenib / Generic mfg.
    Journal:  Caspase-3-induced activation of SREBP2 drives drug resistance via promotion of cholesterol biosynthesis in hepatocellular carcinoma. (Pubmed Central) -  Sep 10, 2022   
    Simvastatin, an FDA-approved cholesterol-lowering drug, not only suppressed HCC tumor growth but also sensitized HCC cells to sorafenib. These findings demonstrate that CSC populations in HCC expand via CASP3-dependent, SREBP2-mediated cholesterol biosynthesis in response to tyrosine kinase inhibitor therapy and that targeting cholesterol biosynthesis can overcome acquired drug resistance.
  • ||||||||||  Balversa (erdafitinib) / J&J
    FGFR IS A RELEVANT MOLECULAR TARGET IN PEDIATRIC AND AYA SARCOMAS () -  Sep 9, 2022 - Abstract #CTOS2022CTOS_308;    
    In summary, activating FGFR alterations were found in 18 pediatric sarcomas sequenced through the Profile and GAIN/iCAT2 studies, identifying a population of children with cancer who may be eligible and good candidates for trials evaluating FGFR-targeted therapy. Importantly, the genomic and clinical data from this study can help inform drug development in accordance with the RACE for Children Act.
  • ||||||||||  Review, Journal:  Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications. (Pubmed Central) -  Sep 7, 2022   
    The HIF-2α inhibitor belzutifan has recently received regulatory approval for the treatment of tumors arising in the context of Von-Hippel Lindau syndrome including pancreatic NENs, and a study of this drug in patients with sporadic tumors is presently ongoing...The potential of antiangiogenic agents in fine-tuning the immune microenvironment of NENs to enhance the activity of immune checkpoint inhibitors has been only partially elucidated, and further research should be carried out at this regard. Here, we review the current understanding of the biology of angiogenesis in NENs and provide a summary of the latest clinical investigations on antiangiogenic drugs in this malignancy.
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Phase classification, Trial completion date, Trial primary completion date:  Postoperative Adjuvant Therapy of HCC Based on PD-1 (clinicaltrials.gov) -  Sep 7, 2022   
    P=N/A,  N=573, Completed, 
    Here, we review the current understanding of the biology of angiogenesis in NENs and provide a summary of the latest clinical investigations on antiangiogenic drugs in this malignancy. Phase classification: P1/2 --> P=N/A | Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2021 --> Jul 2022
  • ||||||||||  Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System. (clinicaltrials.gov) -  Sep 7, 2022   
    P2,  N=30, Active, not recruiting, 
    Phase classification: P1/2 --> P=N/A | Trial completion date: Apr 2022 --> Aug 2022 | Trial primary completion date: Apr 2021 --> Jul 2022 Not yet recruiting --> Active, not recruiting | Trial completion date: Jan 2023 --> Dec 2023 | Trial primary completion date: Mar 2022 --> Jul 2022
  • ||||||||||  Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    HCC Recurrence Post Liver Transplant With Rapid Progression in a Patient Presenting With Elevated Transaminases (Crown Ballroom) -  Sep 4, 2022 - Abstract #ACG2022ACG_1813;    
    He was later noted to have widespread metastatic disease involving the liver, bones, peritoneum, and left adrenal gland and was started on Lenvatinib...Our case is important as it highlights the unmet needs for systemic therapy in post-transplant patients and the need to maintain a high level of suspicion for rapid progression of diffusely infiltrative cancer in the differential diagnosis for dramatic elevation of the transaminases in select patient populations. Figure: MRI abdomen with and without contrast demonstrating extensive tumor burden of HCC in transplanted liver.